Compare FKWL & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | PSTV |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 34.5M |
| IPO Year | 1997 | 2016 |
| Metric | FKWL | PSTV |
|---|---|---|
| Price | $2.62 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $55.00 |
| AVG Volume (30 Days) | 32.2K | ★ 134.5K |
| Earning Date | 05-15-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | $7.14 | $261.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $2.61 | $0.13 |
| 52 Week High | $5.48 | $8.00 |
| Indicator | FKWL | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 26.20 | 30.82 |
| Support Level | N/A | $0.37 |
| Resistance Level | $3.79 | $6.65 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 2.00 | 5.18 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).